诺和诺德与BioMarin布局人工智能领域；百时美施贵宝迎来卫材神经学高管加盟。
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
生命科学资讯
生物技术与制药领域的最新动态
一家复合药店对礼来、诺和诺德提起反垄断诉讼
A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
FDA将就问题工厂与诺和诺德会面；艾伯维收购药物设备工厂。
FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
诺和诺德基金会向丹麦本土生物技术培育机构投资8.6亿美元。
Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs
诺和诺德基金会计划至2035年向生物创新研究院注资超8.5亿美元。
Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
#JPM26：诺和诺德CEO称制药业可从GLP-1药物复配热潮中汲取经验
#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom
诺和诺德推出Wegovy口服药，医保患者月费25美元，自费149美元。
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
诺和诺德减肥药获美国FDA批准。
Novo Nordisk’s weight loss pill approved by FDA
诺和诺德获FDA批准减肥药，期待强劲上市表现。
Novo Nordisk eyes a strong launch with FDA approval of obesity pill
诺和诺德因收购的Catalent工厂收到FDA警告信。
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
诺和诺德药物Amycretin在二期糖尿病试验中减轻体重并降低血糖
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Novo Nordisk的semaglutide在高度关注的阿尔茨海默病试验中失败了
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
#Novo Nordisk#closely-watched Alzheimer#long shot#long shots#Nordisk semaglutide
Novo Nordisk的GLP-1在受到关注的阿尔茨海默病研究中missed目标
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies
#Novo Nordisk#watched Alzheimer#misses goal#heart health#combat neurodegeneration
2025-2033年生物技术市场治疗创新与预测报告：聚焦龙沙、安进、先正达、百康、百健、罗氏、诺华、诺和诺德、辉瑞及西雅图遗传学公司 - ResearchAndMarkets.com - 商业电讯
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire
#Therapeutic Innovations#Forecast Report#Featuring Lonza#Novo Nordisk#Market Therapeutic